Notes to Accounts of Vivanza Biosciences Ltd.

Mar 31, 2024

> Contingent Liabilities

There is no contingent liability as informed by management.

> Capital Expenditure Commitments: Nil

> Related Party Transactions:-

As per Indian Accounting Standard (Ind AS -24) issued by the Institute of Chartered Accountants of
India, the disclosures of transactions with the related parties are given below:

List of related parties where control exists and related parties with whom transactions have
taken place and relationships:

> Details of loan made during the year 2023-24 as per section 186(4) of The Companies Act 2013

The particulars of loans given, investments made, guarantees given and securities provided along
with the purpose for which the loan or guarantee or security is proposed to be utilised as per the
provisions of Section 186 of the Act are provided in the standalone financial statements. (Please
refer to Notes to the standalone financial statements).

> Capital Management

The Company manages its capital to ensure that entities in the Company will be able to continue
as going concerns whilemaximizing the return to stakeholders through the optimization of the
debt and equity balance. The capital structure of theCompany consists of net debt (borrowings
offset by cash and bank balances) and total equity of the Company.

* Excluding investments in subsidiaries, joint control entities and associates measured at cost in
accordance with Ind AS-27

Fair value hierarchy

The following section explains the judgments and estimates made in determining the fair values of the
financial instruments that are recognized and measured at fair value through profit or loss. To provide an
indication about the reliability of the inputs used in determining fair value, the Company has classified its
financial investments into the three levels prescribed under the accounting standard. An explanation of
each level follows underneath the table.

Level 1 hierarchy includes financial instruments measured using quoted prices (unadjusted) in active
market foridentical assets that the entity can access at the measurement date. This represents
mutual funds that have pricequoted by the respective mutual fund houses and are valued
using the closing Net asset value (NAV).

Level 2 hierarchy includes the fair value of financial instruments measured using quoted prices for
identical or similarassets in markets that are not active.

Level 3 if one or more of the significant inputs is not based on observable market data, the instrument
is included inlevel 3. This is the case for unlisted compound instruments.

There are no transfers between any of these levels during the year. The Company''s policy is to recognize
transfersinto and transfers out of fair value hierarchy levels as at the end of the reporting period.

C. Fair value of financial assets and liabilities measured at amortized cost

The Management has assessed that fair value of loans, trade receivables, cash and cash equivalents,
other bankbalances, other financial assets and trade payables approximate their carrying amounts
largely due to their short term nature. Difference between carrying amount of Bank deposits, other

financial assets, borrowings and otherfinancial liabilities subsequently measured at amortized cost is not
significant in each of the years presented.

For financial assets and liabilities that are measured at fair value, the carrying amounts are equal to the
fair values.

> Financial risk management

The Company''s board of directors has overall responsibility for the establishment and oversight of the
Company''s risk management framework. The board has established the Audit Committee, which is
responsible for developing and monitoring the Company''s risk management policies. The Committee
holds regular meetings and report to board on its activities. The Company''s risk management policies
are established to identify and analyses the risks faced by the Company, to set appropriate risk limits
and controls and to monitor risks and adherence to limits. Risk management policies and systems are
reviewed regularly to reflect changes in market conditions and the Company''s activities. The Company,
through its training and management standards and procedures, aims to maintain a disciplined and
constructive control environment in which all employees understand their roles and obligations. The
audit committee oversees how management monitors compliance with the Company''s risk
management policies and procedures, and reviews the adequacy of the risk management framework in
relation to the risks faced by the Company. The audit committee is assisted in its oversight role by
internal audit. Internal audit undertakes both regular and ad hoc reviews of risk management controls
and procedures, the results of which are reported to the audit committee.

(a) Credit risk

Credit risk is the risk of financial loss to the company if a customer or counterparty to a financial
instrument fails to meet its contractual obligations. The company is exposed to the credit risk from its
trade receivables, unbilledrevenue, investments, cash and cash equivalents, bank deposits and other
financial assets. The maximum exposure to credit risk is equal to the carrying value of the financial
assets. The objective of managing counterparty credit risk is to prevent losses in financial assets.

Trade Receivables

Trade receivables comprise a widespread customer base. Management evaluates credit risk relating
to customers on an on-going basis. If customers are independently rated, these ratings are used.
Otherwise, if there is no independent rating, risk control assesses the credit quality of the customer,
taking into account its financial position, past experience and other factors

(b) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations
associated with its financial liabilities that are settled by delivering cash or another financial asset. The
Company''s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient
liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without
incurring unacceptable losses or risking damage to the Company''s reputation.

Liquidity Table

The Company''s remaining contractual maturity for its non-derivative financial liabilities with agreed
repayment periods is given below. The tables have been drawn up based on the undiscounted cash
flows of financial liabilities based on the earliest date on which the Company can be required to pay.
The tables include both interest and principal cash flows. The contractual maturity is based on the
earliest date on which the Company may be required to pay.

(c) Market Risk

Market risk is the risk arising from changes in market prices - such as foreign exchange rates and
interest rates - willaffect the Company''s income or the value of its holdings of financial instruments.
The Company is exposed to market risk primarily related to interest rate risk and themarket value of
the investments. Thus, the exposure to market risk is a function of investing and borrowing activities

- Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will
fluctuate because of changes in market interest rates.

Most of the Company''s borrowings are on a floating rate of interest. The Company has exposure to
interestrate risk, arising principally on changes in Marginal Cost of Funds based Lending Rate (MCLR).
The Companyuses a mix of interest rate sensitive financial instruments to manage the liquidity and
fund requirements for itsday to day operations like short term credit lines besides internal accruals.

(d) Price Risk
Exposure

The Company''s exposure to securities price risk arises from investments held in mutual funds and
classified in the balance sheet at fair value through profit or loss. To manage its price risk arising from
such investments, the Company diversifies its portfolio. Further these are all debt base securities for
which the exposure is primarily on account of interest rate risk. Quotes (NAV) of these investments
are available from the mutual fund houses. Profit for the year would increase/decrease as a result of
gains/losses on these securities classified as at fair value through profit or loss.

> Others

- Balance Sheet is still carrying Opening Balance of "P & P Expenses and issue related expenses of Rs.
7.32/-(In Lakhs) as "Other Current Assets", which in our opinion needs to be written off in Two
Financial Years proportionately. And Due to the same expense is under stated in profit & loss account.

- Balance of sundry debtors and creditors, loans and advances accepted and given in the balance sheet
are subject to confirmation.

- As informed by the management that the loans are interest free, which in our opinion is violation of
Section 186 (7) of the Companies Act, 2013.

- Above Disclosure is made after taking into account the principle of materiality.

- In the events of non-availability of suitable supporting vouchers, Directors have given us certificate
that these expenses are incurred mainly for the business activities of the company.

- The previous year''s figures have been reworked, regrouped, rearranged and reclassified wherever
necessary. Amounts and other disclosures for the preceding year are included as an integral part of
the current year financial statements and are to be read in relation to the amounts and other
disclosures relating to the current year.

For, Vivanza Biosciences Limited

For, SHIVAM SONI & Co.

Jainil Bhatt Chartered Accountants

CFO FRN: 152477W

Parikh H.A. Mehta J.A. Avinash G Bhojwani CA Shivam Soni

Director Managing Director Company Secretary Proprietor

DIN: 00027820 DIN:08210602 Memberships No. 178351

UDIN:24178351BKEPOB8943

Place: Ahmedabad
Date:30/04/2024

---

Mar 31, 2014

I. ADDITIONAL NOTES (Forming an integral part of Accounts)

1. In opinion of the management of the company, all loans, advances and deposits are recoverable in cash or kind for value to be received for which no provision is required. However in the opinion of the Auditors, it shall be prudent to make sufficient provision for such non performing assets amounting to Rs. 59,33,061/-.

2 Contingent liabilities for claims against company not acknowledged and not provided for amounts to Rs. 5,01,271/- (P.Y. Rs. 5,01,271/-). As ascertained and certified by the management there is no other contingent liability for which provision is required.

3 Balance of all personal accounts including Sundry debtors, Sundry creditors, Loans and Advances, Deposits etc. are subject to confirmation, reconciliation and appropriate adjustment.

4. The Composite Scheme of Re-organisation of Share Capital and Arrangement for Revival of the Company filed with the Stock Exchange and SEBI under Clause 24(f) of the Listing Agreement had been withdrawn by the Company in view of observations received from BSE requires revision of the Scheme.

5. Segment Report :

The company is exclusively engaged in the business of manufacture and sale of I.V. fluids, Pharmaceuticals products in India and there is no other segmental activities hence no separate disclosure of reportable segment is required.

---

Mar 31, 2013

1. There is no movement of the shares outstanding at the beginning and at the end of the reporting period.

2. The Company has only one class of equity shares having a par value of Rs. 10 per share. Each shareholder is elligible for one vote per share. The dividend proposed by the Board of Directors is subject to the approval of shareholders, except in case of interim dividend in the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company, after distribution of all preferential amounts, in proportion of their shareholding.

3. Company has not alloted any bonus shares, Shares without consideration in cash and/or bought back any equity shares during the priod of five years immediately preceeding the Balance sheet date.

4. In opinion of the management of the company, all loans, advances and deposits are recoverable in cash or kind for value to be received for which no provision is required. However in the opinion of the Auditors, it shall be prudent to make sufficient provision for such non performing assets amounting to Rs. 59,33,061/-.

5 Contingent liabilities for claims against company not acknowledged and not provided for amounts to Rs. 5,01,271/- (P.Y. Rs. 5,01,271/-). As ascertained and certified by the management there is no other contingent liability for which provision is required.

6 Balance of all personal accounts including Sundry debtors, Sundry creditors, Loans and Advances, Deposits etc. are subject to confirmation, reconciliation and appropriate adjustment.

7 DISCLOSURE ON RELATED PARTIES:

Name of the related parties & nature of the relationship

A) Associate Company:

1) M/s. Ivee Plasticaa (GUJ.) Pvt. Ltd.

2) M/s. Nirman Infrastructure Ltd.

In which our Director Dr. N. V. Vasavada is director. Inter corporate loan & advances given to them earlier which remains outstanding as on 31.03.2013 Rs. 31,35,000/- maximum balance during the year Rs. 31,35,000/- in opinion of auditor same is doubtful of recovery however the directors are hopeful of recovery.

8. Segment Report :

The company is exclusively engaged in the business of manufacture and sale of Ivee fluids, Pharmaceuticals products in India and there is no other segmental activities hence no separate disclosure of reportable segment is required.

9. Earning & Expenditure in Foreign Currency : NIL

10. Previous year figures have been regrouped and/or rearranged whenever necessary.

---

Mar 31, 2011

1) No Provision for gratuity and earned leave has been made in accordance with labour law consultant's advice. Actuarial valuation in this regard is yet to be made.

2) Company has in earlier year adjusted the debit balance of Profit & Loss account aggregating to Rs. 96,27,661/- against the credit lying in revaluation reserve account, which in the opinion of auditors, is not in the accordance with the Accounting Standard recommended by the Institute of Chartered Accountants of India. As a result of this adjustment, the credit balance of revolution reserve and debit balance of Profit & Loss A/c gets under stated by the said sums. The management of the Company intends to pass corrective entries, if required prior to declaration of dividend.

3) Contingent liabilities for claims against company not acknowledged and not provided for amounts to Rs. 5,01,271/- (P.Y. Rs. 5,01,271/-). As ascertained and certified by the management there is no other contingent liability for which provision is required.

4) Considering the carried forward assessed losses no provision of Income Tax is required.

5) Balance of all personal accounts including Sundry debtors, Sundry creditors, Loans and Advances, Deposits etc. are subject to confirmation, reconciliation and appropriate adjustment.

6) DISCLOSURE ON RELATED PARTIES:

Name of the related parties & nature of the relationship A) Associate Company:

1) M/s. Ivee Plasticaa (GUJ.) Pvt. Ltd.

2) M/s. Nirman Infrastructure Ltd.

In which our Director Dr. N. V. Vasavada is director. Inter corporate loan 8, advances given to them earlier which remains outstanding as on 31.03.2011 Rs. 31,35,000/- maximum balance

during the year Rs. 31,35,000/- in opinion of auditor same is doubtful of recovery however the directors are hopeful of recovery.

B) Key Management Person : 1) Mr. H. D. Nanavati - M.D.

7) Segment Activities Discloser:

The company is exclusively engaged in the business of manufacture and sale of Ivee fluids, Pharmaceuticals products in India and there is no other segmental activities hence no separate disclosure of reportable segment is required.

8) Accounting for Taxes on Income:

Considering the loss in the current year, accounting for taxes on income for current year's tax liability is NIL. The management of the Company is of the opinion that there is virtual uncertainty of realization of the benefit of past losses and differed tax assets. As such the accounting of such deferred tax assets and taxes thereon is not recognized.

9) In absence of any manufacturing activity, the particulars required under Clause 4C & 4D of Part - II of Schedule - VI is not given.

10) Earning & Expenditure in Foreign Currency : NIL

---

Mar 31, 2010

Not Available